跳至主要内容
临床试验/NL-OMON29407
NL-OMON29407已完成不适用

Three arm randomized parallel phase II/III study evaluating the efficacy and safety of the combinations Epirubicin and Taxotere (ET), Taxotere and Navelbine (TN) and Navelbine and Epirubicin (EN) as first line therapy in patients with metastatic breast cancer.

VU medical center.0 个研究点目标入组 111 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
111

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Histologically proven breast cancer at first diagnosis. At study entry histological or cytological proof of metastasis is required in case of a single metastatic target lesion.
  • Female metastatic breast cancer patients
  • Measurable disease or evaluable disease (bone metastases only allowed).

排除标准

  • 1. Prior chemotherapy for metastatic disease.
  • 2. Locally advanced inoperable breast cancer (Stage III B) as only manifestation of the disease.

研究者

发起方
VU medical center.

相似试验